Expert Interviews
Advertisement
Ravi Rajaram, MD, MSc, discusses Medicaid expansion, timely access to care, regionalization effects, and remaining questions.
Michael R. Gieske, MD, discusses why Lung Cancer Action Week is a key time to promote screening and shares recent milestones.
Dr. Liu discusses his experience as co-chair of the Texas Lung Cancer Conference and shares key highlights.
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
Mara Antonoff, MD, discusses key advances and addresses common misconceptions about operating in oligometastatic disease.
Dr. Weiss noted the results in both feasibility and safety, particularly via injection, which had limited complications.
Dr. Mara Antonoff discusses why it's critical to offer information and updates on surgery for oligometastatic lung cancer.
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
Nicolas Girard, MD, PhD, discusses data on subcutaneous amivantamab in patients with advanced NSCLC.
The session covered everything from new actionable immune checkpoints to vaccines, cellular therapies, and bispecifics.
Martin Reck, MD, PhD, reflects on key updates in stage III NSCLC from the European Lung Cancer Congress 2025.
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Dr. Liu shares what he's looking forward to during the European Lung Cancer Congress, which will be held March 26-29.
The NCCN 2025 Annual Conference will be held from March 28-30 in Orlando, Florida.
Mara B. Antonoff, MD, FACS, discusses the organization's mission, the resources it offers, and her hopes for the future.
Dr. Liu unpacks key questions in the field, and the research that could address them.
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
Dr. Liu unpacks the trial results, the recent approval, and the unique biomarker testing considerations for NRG1 fusions.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.